Table 1.
Contraceptive Progestins
| Progestin-type | Steroid class | Progestin generation |
Class members | Common Contraceptives |
Delivery route(s) |
Notes |
|---|---|---|---|---|---|---|
| Progesterone derivatives |
Pregnanes | n/a | MPA | DMPA | Injectable* | |
|
| ||||||
| Testosterone derivatives |
Estranes | 1st | Norethindrone | Multiple progestin only and combined oral formulations |
Oral | Of the testosterone derivative progestins: Lowest progestational effect; lowest potency; shortest half-life (T1/2). |
|
|
||||||
| Norethindrone acetate |
Multiple combined oral formulations |
Oral | ||||
|
|
||||||
| Norethindrone enanthate§ |
NET-En | Injectable | ||||
|
|
||||||
| Ethynodiol diacetate |
Several combined oral formulations |
Oral | ||||
|
|
||||||
| Gonanes | 2nd | Norgestrel | Multiple combined oral formulations |
Oral | 2nd generation progestins have higher andreogenic effects compared with other progestins |
|
|
|
||||||
| Levonorgestrel | Multiple combined oral formulations |
Oral | ||||
|
|
||||||
| Mirena®/Skyla® | Intrauterine | |||||
|
|
||||||
| Norplant®/Jadelle®§ | Subdermal implants |
|||||
|
|
||||||
| 3rd | Desogestrel | Multiple combined oral formulations |
Oral | 3rd generation progestins have higher affinity for the progesterone receptor and lower affinity for the androgen receptor compared with 1st and 2nd gen. progestins |
||
|
|
||||||
| NuvaRing® | Intravaginal | |||||
|
|
||||||
| Implanon®/Nexplanon® | Subdermal Implants |
|||||
|
|
||||||
| Norgestimate | Multiple oral formulations | Oral | ||||
|
|
||||||
| Gestodene§ | Several oral formulations | Oral | ||||
|
| ||||||
| Spironolactone derivatives |
n/a | 4th | Drospirenone | Multiple oral formulations | Oral | Increased anti- mineralocorticoid and anti- androgenic properties compared with other progestins |
Intramuscular and subcutaneous injectable formulations available
Not available in the United States